ASCO 2016 | Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)

Charles Rudin

Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter